Reference
Hayman DTS, et al. Cost-benefit analyses of supplementary measles immunisation in the highly immunized population of New Zealand. Vaccine : 10 Aug 2017. Available from: URL: http://dx.doi.org/10.1016/j.vaccine.2017.07.077
Rights and permissions
About this article
Cite this article
Economic benefits for catch-up measles vaccination in NZ. PharmacoEcon Outcomes News 785, 10 (2017). https://doi.org/10.1007/s40274-017-4260-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4260-9